Cormorant Asset Management »

Janux Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Janux Therapeutics (JANX) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Janux Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Janux Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Janux Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $44M 1.1M 41.89
2024-03-31 $28M 750k 37.65

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Arcellx Common Stock (ACLX)
Vaxcyte (PCVX)
Longboard Pharmaceuticals In (LBPH)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Crinetics Pharmaceuticals In (CRNX)
Edgewise Therapeutics (EWTX)
Merus N V (MRUS)
Bridgebio Pharma (BBIO)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Janux Therapeutics (JANX)
Axsome Therapeutics (AXSM)

View all positions for Cormorant Asset Management

Top funds holding Janux Therapeutics

RA Capital Management
BlackRock
Paradigm Biocapital Advisors
BlackRock
Henderson Group
Woodline Partners
Vanguard Group
EcoR1 Capital
State Street Corporation
OrbiMed Advisors
Citadel Advisors
Cormorant Asset Management
Logos Global Management
Lord, Abbett & Co
Geode Capital Management

View all funds holding Janux Therapeutics